Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dizal Pharmaceutical Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is being handled by 1 distinct examiner, SCHMIDT, IZABELA MARIA. The concentration of work is absolute, as 1 distinct art unit contains the entirety of the portfolio's active prosecution. SCHMIDT, IZABELA MARIA is identified as the busiest examiner for the company, also accounting for 1 busiest examiner pending action.
This indicates a highly focused prosecution stage where all current activity is channeled through a single point of contact at the patent office. Practitioners can expect a streamlined communication path given the lack of diversity in assigned personnel. The alignment of the busiest examiner with the only pending action suggests that the company's immediate patent strategy is entirely dependent on the outcomes from this specific individual. Furthermore, the presence of 1 distinct art unit implies that the technical subject matter is tightly defined within the Biotechnology & Pharmaceuticals sector. This singular art unit assignment simplifies the consistency of legal arguments across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMIDT, IZABELA MARIA | 1 | 65.3% | +42.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18473282 | ERBB/BTK INHIBITORS | SCHMIDT, IZABELA MARIA | 26d |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18473282 | ERBB/BTK INHIBITORS | SCHMIDT, IZABELA MARIA | 1621 | §112Other | Non-Final OA | 26d | Pending | Sep 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial